Analysis of ibuzatrelvir's activity against SARS-CoV-2 circulating variants and in vitro resistance mutations.

doi:10.1016/j.antiviral.2026.106352

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Analysis of ibuzatrelvir's activity against SARS-CoV-2 circulating variants and in vitro resistance mutations.

Antiviral research - 1 Apr 2026

Yurgelonis Irina, Rai Devendra K, Li Zhenghui, Washington Brittany, McMonagle Patricia, Noell Stephen, Plotnikova Olga, Nicki Jennifer, Craig Timothy K, Yang Qingyi, Titova Elizabeth, Lee Kwok, Behzadi Mohammad Amin, Rothan Hussin, Nguyen Ha H, Coffey Todd, Lee Jonathan T, Zhu Yuao, Hao Li, Kreiswirth Barry N, Cardin Rhonda D, Allerton Charlotte M N, Najera Isabel

Abstract excerpt

The continued evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) underscores the ongoing need for effective antiviral therapies targeting this now-endemic virus. Ibuzatrelvir, a second-generation SARS-CoV-2 main protease (Mpro) inhibitor, has demonstrated potent antiviral activity without the need for a pharmacokinetic booster such as ritonavir. In the present study, we show that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Substitution

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antiviral Agents

Share to Azabicyclo Compounds

Share to Coronavirus 3C Proteases

Share to COVID-19 Drug Treatment

Share to Drug Resistance, Viral

Share to Pyrrolidinones

Share to SARS-CoV-2

Source

Open in PubMed

Identifiers

PMID: 41621598
DOI: 10.1016/j.antiviral.2026.106352

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of ibuzatrelvir's activity against SARS-CoV-2 circulating variants and in vitro resistance mutations.PMID 41621598Read ↗

Antiviral Activity of Remdesivir and Obeldesivir Against SARS-CoV-2 Omicron Subvariants That Were Circulating from September 2023 Through June 2025.Semantic proximity Read ↗

Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populationsSemantic proximity Read ↗

SABRes: in silico detection of drug resistance conferring mutations in subpopulations of SARS-CoV-2 genomes.Semantic proximity Read ↗

A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 VariantsSemantic proximity Read ↗

Cross-resistance patterns in SARS-CoV-2 against 3CL protease inhibitors.Semantic proximity Read ↗

Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variantsSemantic proximity Read ↗

Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrierSemantic proximity Read ↗

SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participantsSemantic proximity Read ↗

In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2.Semantic proximity Read ↗

Clinical experience of treatment of immunocompromised individuals with persistent SARS-CoV-2 infection based on drug resistance mutations determined by genomic analysis: a descriptive study.Semantic proximity Read ↗

Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent <i>in vitro</i> activity against the SARS-CoV-2 Omicron variantSemantic proximity Read ↗

Novel Mechanisms of SARS-CoV-2 Drug Resistance and Rational Design of Anti-Resistant Antivirals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.